The Vanguard Group 13D and 13G filings for Fate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:04 pm Sale |
2023-12-29 | 13G | Fate Therapeutics, Inc. FATE |
The Vanguard Group | 9,293,363 9.430% |
-642,679 (-6.47%) |
Filing |
| 2023-03-10 07:59 am Purchase |
2023-02-28 | 13G | Fate Therapeutics, Inc. FATE |
The Vanguard Group | 9,936,042 10.120% |
1,963,491 (+24.63%) |
Filing |
| 2023-02-09 11:19 am Purchase |
2022-12-30 | 13G | Fate Therapeutics, Inc. FATE |
The Vanguard Group | 7,972,551 8.200% |
296,764 (+3.87%) |
Filing |
| 2022-02-10 08:11 am Purchase |
2021-12-31 | 13G | Fate Therapeutics, Inc. FATE |
The Vanguard Group | 7,675,787 8.040% |
897,200 (+13.24%) |
Filing |
| 2021-02-10 10:52 am Purchase |
2020-12-31 | 13G | Fate Therapeutics, Inc. FATE |
The Vanguard Group | 6,778,587 7.770% |
6,778,587 (New Position) |
Filing |